Results 171 to 180 of about 2,763 (183)

Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine

Regulatory Toxicology and Pharmacology, 2019
Antoinette Maassen van den Brink, Hugo M Vargas, Eloisa Rubio-Beltrán   +2 more
exaly  

Hypertension with erenumab

Reactions Weekly, 2021
openaire   +1 more source

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

Cephalalgia, 2019
Uwe Reuter, David Dodick
exaly  

Erenumab During Breastfeeding

Breastfeeding Medicine, 2019
openaire   +2 more sources

Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab

Cephalalgia, 2018
Dana Franznick, Uwe Reuter, Richard Lipton   +2 more
exaly  

Erenumab Side Effects

Headache: The Journal of Head and Face Pain, 2019
openaire   +2 more sources

Erenumab/Galcanezumab

Reactions Weekly
  +4 more sources

Erenumab/Fremanezumab

Reactions Weekly
openaire   +2 more sources

Erenumab/fremanezumab/galcanezumab

Reactions Weekly, 2019
openaire   +1 more source

Zulassungsempfehlung für Erenumab

Schmerzmedizin, 2018
openaire   +1 more source